Outlook Therapeutics amends warrants to $0.5855 exercise price for offering participants

Outlook Therapeutics reduced the exercise price of existing warrants from $1.40-$2.26 to $0.5855 per share for investors participating in a registered direct offering. The amendment makes warrant conversion more attractive and could signal shareholder dilution concerns.